1,317 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Acquired by Oarsman Capital Inc.

Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,317 shares of the company’s stock, valued at approximately $29,000.

Several other hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $66,000. IFP Advisors Inc lifted its holdings in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after purchasing an additional 1,960 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $104,000. Finally, Assetmark Inc. increased its stake in Teva Pharmaceutical Industries by 1,370.3% during the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock worth $115,000 after purchasing an additional 4,851 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TEVA. Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Friday. UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Bank of America reduced their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $13.83 on Monday. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a market cap of $15.68 billion, a P/E ratio of -9.54, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock’s 50-day simple moving average is $16.52 and its 200 day simple moving average is $18.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.